Digoxin in Heart Failure with a Reduced Ejection Fracti

Cardiology
134, 311-319
DOI: 10.1159/000444078

Citation Report

#	Article	IF	Citations
1	Recent advances in cardiology.. Postgraduate Medical Journal, 1982, 58, 459-466.	0.9	1
2	A new look at digoxin in congestive heart failure and sinus rhythm. Postgraduate Medical Journal, 1989, 65, 715-717.	0.9	2
3	The use of digitalis for the treatment of congestive heart failure: A tale of its decline and resurrection. Cardiovascular Drugs and Therapy, 1989, 3, 473-476.	1.3	7
4	The rationale for combined use of diuretics, digitalis, and vasodilators in congestive heart failure. Cardiovascular Drugs and Therapy, 1989, 3, 13-17.	1.3	0
5	Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.. British Journal of Clinical Pharmacology, 1991, 31, 1-13.	1.1	30
6	Risks and Benefits of the Treatment of Heart Failure Current Status. Drug Safety, 1991, 6, 277-284.	1.4	0
7	Angiotensin Converting Enzyme Inhibitors Versus Digoxin for the Treatment of Congestive Heart Failure. Drugs, 1992, 43, 637-650.	4.9	10
8	Digitalis and heart failure: Does digitalis really produce beneficial effects through a positive inotropic action?. Cardiovascular Drugs and Therapy, 1992, 6, 459-464.	1.3	4
9	Digoxin is effective, but is it safe?. Cardiovascular Drugs and Therapy, 1993, 7, 893-896.	1.3	9
10	Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin. Cardiovascular Drugs and Therapy, 1993, 7, 349-356.	1.3	15
11	Ibopamine. Drugs and Aging, 1993, 3, 556-584.	1.3	12
12	Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.. Heart, 1994, 72, 509-513.	1.2	74
13	Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after heart transplantation.. Heart, 1994, 71, 422-430.	1.2	120
14	Treatment of end stage dilated cardiomyopathy. Heart, 1994, 72, S52-S56.	1.2	4
15	Inotropic agents for heart failure: what if digoxin increases mortality?. Heart, 1994, 72, S92-S99.	1.2	13
16	Myocardial phenotype changes in heart failure: cellular and subcellular adaptations and their functional significance. Heart, 1994, 72, S10-S17.	1.2	20
17	Pharmacotherapy of congestive heart failure. International Journal of Clinical Pharmacy, 1994, 16, 334-342.	1.4	8
18	Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure. European Journal of Clinical Pharmacology, 1994, 47, 325-330.	0.8	1

#	Article	IF	Citations
19	Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. Cardiovascular Drugs and Therapy, 1994, 8, 761-768.	1.3	3
20	Role of Patient Compliance in Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1994, 27, 202-215.	1.6	161
21	Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose. Cardiovascular Drugs and Therapy, 1995, 9, 723-729.	1.3	31
22	Influence of resting sympathetic activity on reflex sympathetic responses in normal man. Clinical Autonomic Research, 1995, 5, 71-80.	1.4	26
23	Cardiac Glycosides Drug Interactions of Clinical Significance. Drug Safety, 1995, 12, 97-109.	1.4	19
24	Digoxin in the Treatment of Patients with Chronic Heart Failure. Drugs and Aging, 1995, 7, 1-9.	1.3	3
25	Clinical and Economic Factors in the Treatment of Congestive Heart Failure. Pharmacoeconomics, 1995, 7, 119-127.	1.7	31
26	Current Guidelines for the Treatment of Congestive Heart Failure. Drugs, 1996, 51, 89-98.	4.9	18
27	Novel Drugs and Current Therapeutic Approaches in the Treatment of Heart Failure. Drugs, 1996, 51, 347-358.	4.9	13
28	The Economics of Cardiac Failure. Journal of the Royal Society of Medicine, 1996, 89, 9-12.	1.1	2
29	Hemodynamic correlates of baroreflex impairment of heart rate in experimental canine heart failure. Basic Research in Cardiology, 1996, 91, 147-154.	2.5	17
30	Medical treatment of eng-stage heart failure. Cardiovascular Drugs and Therapy, 1996, 10, 617-622.	1.3	2
31	Effect of epinine on tension of human renal arteries. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 343-7.	1.4	3
32	Cardioversion of atrial fibrillation.. Postgraduate Medical Journal, 1996, 72, 126-126.	0.9	0
33	Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure.. Heart, 1996, 75, 159-164.	1.2	14
34	Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart, 1997, 78, 564-568.	1.2	83
35	The management of congestive heart failure.. Postgraduate Medical Journal, 1997, 73, 194-200.	0.9	10
36	Comparison of captopril and ibopamine in mild to moderate heart failure.. Heart, 1997, 78, 285-290.	1.2	12

#	Article	IF	Citations
37	Exercise for Patients with Congestive Heart Failure. Sports Medicine, 1997, 23, 75-92.	3.1	34
38	When, and When Not, to Use Digoxin in the Elderly. Drugs and Aging, 1997, 10, 411-420.	1.3	13
39	Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clinical Cardiology, 1997, 20, 949-954.	0.7	74
41	Pharmacological Therapy of Cardiac Arrhythmias. Journal of Thrombosis and Thrombolysis, 1998, 6, 211-238.	1.0	0
42	Effects of dichloroacetate in patients with congestive heart failure. Clinical Cardiology, 1998, 21, 888-892.	0.7	63
44	Digoxin Use in Congestive Heart Failure. Drugs, 1998, 55, 747-758.	4.9	22
45	Health economics of heart failure. Heart, 1999, 82, 11iv-13.	1.2	24
46	Clinical case studies in heart failure management. British Journal of Clinical Pharmacology, 1999, 47, 239-247.	1.1	0
47	Symptomatic systolic ventricular failure. Current Cardiology Reports, 1999, 1, 20-28.	1.3	0
48	Review of the cardiac insufficiency bisoprolol study II (CIBIS-II). Current Cardiology Reports, 1999, 1, 29-30.	1.3	2
49	Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: Patient selection, non-selective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy. Current Cardiology Reports, 1999, 1, 47-54.	1.3	1
50	Beta-blockers and amiodarone for the primary prevention of sudden cardiac death. Current Cardiology Reports, 1999, 1, 274-281.	1.3	4
51	Beta blockade improves survival in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 101-103.	0.4	0
52	Chronic heart failure. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 231-241.	0.4	3
53	Inappropriate Use of Digoxin in the Elderly. Drug Safety, 1999, 20, 223-230.	1.4	14
54	??-Blockers in Heart Failure. Drugs, 1999, 58, 203-210.	4.9	36
55	The evidence for beta Âblockers in heart failure. BMJ: British Medical Journal, 1999, 318, 824-825.	2.4	95
56	Left ventricular dysfunction among elderly patients in general practice. BMJ: British Medical Journal, 1999, 318, 1483-1483.	2.4	1

#	Article	IF	Citations
57	Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ: British Medical Journal, 2000, 320, 220-224.	2.4	73
58	Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ: British Medical Journal, 2000, 321, 1113-1116.	2.4	21
59	Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity Commentary: Time for a controlled trial?. BMJ: British Medical Journal, 2000, 321, 540-545.	2.4	153
60	The rational use of Î²-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. British Journal of Clinical Pharmacology, 2000, 49, 1-9.	1.1	40
61	Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. British Journal of Clinical Pharmacology, 2000, 50, 15-20.	1.1	18
62	Therapeutics Drugs used in secondary prevention after myocardial infarction: Case presentation. British Journal of Clinical Pharmacology, 2000, 50, 405-417.	1.1	3
63	Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?. , 2000, 1, 95.		2
64	Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. British Journal of Pharmacology, 2000, 130, 1131-1139.	2.7	88
65	Update in Internal Medicine. Archives of Medical Research, 2000, 31, 329-352.	1.5	0
66	The control of adrenergic function in heart failure: therapeutic intervention. , 2000, 5, 101-114.		32
67	Alterations in adrenergic receptor signaling in heart failure. , 2000, 5, 7-16.		42
68	Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. , 2000, 5, 17-25.		87
69	The role of cardiac imaging in optimizing therapy in heart failure. Journal of Nuclear Cardiology, 2000, 7, 81-84.	1.4	1
70	Cardiac autonomic tone and its relation to nonsustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Clinical Cardiology, 2000, 23, 103-108.	0.7	5
71	Overview of the relationship between ischemia and congestive heart failure. Clinical Cardiology, 2000, 23, IV-4-IV-8.	0.7	33
72	New and emerging pharmacologic strategies in the management of chronic heart failure. Clinical Cardiology, 2000, 23, 724-730.	0.7	8
73	Chagas' Heart Disease. Clinical Cardiology, 2000, 23, 883-889.	0.7	272
74	Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure. Clinical Cardiology, 2000, 23, 909-914.	0.7	25

#	Article	IF	Citations
75	Maximizing management of patients with decompensated heart failure. Clinical Cardiology, 2000, 23, III1-III5.	0.7	5
76	Inotropes in the beta-blocker era. Clinical Cardiology, 2000, 23, III11-III16.	0.7	45
77	Beta-blockers and spironolactone in heart failure. Current Cardiology Reports, 2000, 2, 87-89.	1.3	1
78	The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure. Current Cardiology Reports, 2000, 2, 90-98.	1.3	3
79	The myocardial matrix and the development and progression of ventricular remodeling. Current Cardiology Reports, 2000, 2, 112-119.	1.3	33
80	Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. Current Cardiology Reports, 2000, 2, 225-232.	1.3	3
81	Selective or nonselective Î²-adrenergic blockade in patients with congestive heart failure. Current Cardiology Reports, 2000, 2, 252-257.	1.3	1
82	Arrhythmias in heart failure. Current Treatment Options in Cardiovascular Medicine, 2000, 2, 329-339.	0.4	2
83	Cost of treating heart failure in an Irish teaching hospital. Irish Journal of Medical Science, 2000, 169, 241-244.	0.8	10
84	Beta-Blockers and Diuretics in Antihypertensive Therapy: The Debate Continues. Baylor University Medical Center Proceedings, 2000, 13, 379-380.	0.2	1
85	Regular review: Drug treatment in heart failure. BMJ: British Medical Journal, 2000, 320, 1188-1192.	2.4	44
86	Differential Pharmacokinetics of Digoxin in Elderly Patients. Drugs and Aging, 2000, 17, 353-362.	1.3	74
87	Losartan. Drugs and Aging, 2000, 16, 227-250.	1.3	39
88	Optimising Management of Patients with Advanced Heart Failure. Drugs and Aging, 2000, 16, 87-106.	1.3	3
89	??-Blockers For Congestive Heart Failure. Drugs and Aging, 2000, 16, 1-7.	1.3	12
90	Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furosemide. Pharmacoeconomics, 2000, 17, 429-440.	1.7	50
91	Lisinopril. Drugs, 2000, 59, 1149-1167.	4.9	31
92	Metoprolol. Drugs, 2000, 60, 647-678.	4.9	22

#	Article	IF	Citations
93	Role of Growth Hormone in Chronic Heart Failure. Drugs, 2000, 60, 711-719.	4.9	30
94	Effects of ??-Blockers on Neurohormonal Activation in Patients with Congestive Heart Failure. Drugs, 2000, 60, 997-1016.	4.9	16
95	Torasemide. Pharmacoeconomics, 2001, 19, 679-703.	1.7	15
96	Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in Sweden. Pharmacoeconomics, 2001, 19, 901-916.	1.7	30
97	Heart failure in blacks: Etiologic and epidemiologic differences. Current Cardiology Reports, 2001, 3, 191-197.	1.3	20
98	Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia. Current Cardiology Reports, 2001, 3, 219-223.	1.3	0
99	Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving Î²-blocking agents. Current Cardiology Reports, 2001, 3, 224-231.	1.3	37
100	The role of endothelin receptor antagonists in the treatment of chronic heart failure. Current Cardiology Reports, 2001, 3, 232-240.	1.3	3
101	Is there a role for calcium channel blockers in congestive heart failure?. Current Cardiology Reports, 2001, 3, 114-118.	1.3	2
102	Are all Î²-blockers the same for chronic heart failure?. Current Cardiology Reports, 2001, 3, 124-129.	1.3	4
103	Translating heart failure guidelines into clinical practice: Clinical science and the art of medicine. Current Cardiology Reports, 2001, 3, 130-135.	1.3	10
104	Implications of recent heart failure trials for patients with hypertension. Current Cardiology Reports, 2001, 3, 504-510.	1.3	8
105	Dilated cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 451-462.	0.4	1
106	The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 20.	1.5	73
107	Cytokines as new treatment targets in chronic heart failure. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 271.	1.5	39
108	Measurements of left ventricular dimensions using real-time acquisition in cardiac magnetic resonance imaging: comparison with conventional gradient echo imaging. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2001, 13, 101-108.	1.1	8
109	Dobutamine as bridge to angiotensinâ€converting enzyme inhibitorâ€nitrate therapy in endstage heart failure. Clinical Cardiology, 2001, 24, 231-236.	0.7	14
110	Carvedilol in the failing heart. Clinical Cardiology, 2001, 24, 757-766.	0.7	11

#	Article	IF	Citations
111	Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clinical Cardiology, 2001, 24, 786-787.	0.7	8
112	The challenge of prediction and prevention of sudden cardiac death in congestive heart failure. , 2001, 5, 5-8.		3
113	Heart failure therapy at the turn of the century. , 2001, 6, 7-14.		13
114	Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Failure Reviews, 2001, 6, 341-352.	1.7	18
115	Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Failure Reviews, 2001, 6, 325-334.	1.7	11
116	Effect of Beta-Blockade on Autonomic Modulation of Heart Rate and Neurohormonal Profile in Decompensated Heart Failure. Annals of Noninvasive Electrocardiology, 2001, 6, 98-106.	0.5	30
117	Characterization of Î²1 -selectivity, adrenoceptor-Gs -protein interaction and inverse agonism of nebivolol in human myocardium. British Journal of Pharmacology, 2001, 132, 1817-1826.	2.7	51
118	Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. British Journal of Pharmacology, 2001, 133, 1330-1338.	2.7	93
119	Vagus nerve stimulation decreases left ventricular contractilityin vivoin the human and pig heart. Journal of Physiology, 2001, 534, 547-552.	1.3	107
120	Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure. Journal of Cellular and Molecular Medicine, 2001, 5, 125-131.	1.6	2
121	beta Blockers in older persons with heart failure: tolerability and impact on quality of life. British Heart Journal, 2002, 88, 611-614.	2.2	43
122	The effect of high dose digoxin on cytokines in healthy dogs. Mediators of Inflammation, 2002, 11, 261-263.	1.4	0
123	Longitudinal myocardial contraction improves early during titration with metoprolol CR/XL in patients with heart failure. British Heart Journal, 2002, 87, 23-28.	2.2	17
124	Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. British Heart Journal, 2002, 88, 125-130.	2.2	31
125	Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ: British Medical Journal, 2002, 324, 1498-1498.	2.4	187
126	Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ: British Medical Journal, 2002, 325, 1156-1156.	2.4	50
127	Treatment of Heart Failure in Patients with Diabetes Mellitus. Drugs, 2002, 62, 285-307.	4.9	7
128	Quinapril. Drugs, 2002, 62, 339-385.	4.9	15

#	Article	IF	Citations
129	New Approaches to Atrial Fibrillation Management. Drugs, 2002, 62, 2377-2397.	4.9	65
130	Bisoprolol. Drugs, 2002, 62, 2677-2696.	4.9	34
131	Optimising the Use of ??-Blockers in Older Patients with Heart Failure. Drugs and Aging, 2002, 19, 671-684.	1.3	4
132	Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies. Pharmacoeconomics, 2002, 20, 963-977.	1.7	6
133	Should ??-Blockers be Used for the Treatment of Pediatric Patients with Chronic Heart Failure?. Paediatric Drugs, 2002, 4, 771-778.	1.3	25
135	Prevention of left ventricular remodeling after myocardial infarction. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 97-108.	0.4	9
136	Arrhythmias in patients with heart failure. Current Treatment Options in Cardiovascular Medicine, 2002, 4, 467-485.	0.4	20
137	Î²-Adrenergic blocking drugs as antifibrillatory agents. Current Cardiology Reports, 2002, 4, 426-433.	1.3	14
138	Optimizing blood pressure control in the obese patient. Current Hypertension Reports, 2002, 4, 358-362.	1.5	5
139	Cardiac Effects of Chronic Oral Beta-Blockade:. Annals of Noninvasive Electrocardiology, 2002, 7, 379-387.	0.5	16
140	Does racial bias exist in the medical management of heart failure?. Clinical Cardiology, 2002, 25, 479-483.	0.7	5
141	Management of heart failure in the elderly. Heart Failure Reviews, 2002, 7, 89-97.	1.7	51
142	Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Failure Reviews, 2002, 7, 285-300.	1.7	21
143	Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Failure Reviews, 2002, 7, 229-242.	1.7	65
144	The role of echocardiography in the diagnosis and management of heart failure. Heart Failure Reviews, 2003, 8, 181-189.	1.7	30
145	Coronary artery surgery for ischaemic heart failure: the surgeon's view. Heart Failure Reviews, 2003, 8, 175-179.	1.7	0
146	Hibernation and congestive heart failure. Heart Failure Reviews, 2003, 8, 167-173.	1.7	13
147	Outpatient management of heart failure. Heart Failure Reviews, 2003, 8, 345-348.	1.7	5

#	Article	IF	Citations
148	A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 215-222.	0.6	26
149	The prognostic value of QTC interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide. Clinical Cardiology, 2003, 26, 219-225.	0.7	14
150	Reversal of heart failure remodeling: Is it maintained?. Clinical Cardiology, 2003, 26, 419-423.	0.7	4
151	The management of patients with heart failure in a Slovenian community hospital: What has changed between 1997 and 2000?. Wiener Klinische Wochenschrift, 2003, 115, 334-339.	1.0	8
152	Therapies for preventing heart failure. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 337-343.	0.4	0
153	Contemporary medical, surgical, and device therapies for end-stage heart failure. Current Treatment Options in Cardiovascular Medicine, 2003, 5, 487-499.	0.4	7
154	Familial cardiomyopathies: Significant causes of heart failure. Current Cardiology Reports, 2003, 5, 187-192.	1.3	4
156	Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. European Journal of Clinical Pharmacology, 2003, 58, 747-755.	0.8	29
157	Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. Journal of Cellular and Molecular Medicine, 2003, 7, 1-10.	1.6	42
158	A conceptual paradox of MIBG uptake in heart failure: retention with incontinence!. Journal of Nuclear Cardiology, 2003, 10, 700-704.	1.4	14
159	Influence of diabetes mellitus on heart failure risk and outcome. Cardiovascular Diabetology, 2003, 2, 1.	2.7	163
160	Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods. British Journal of Clinical Pharmacology, 2003, 55, 299-306.	1.1	9
161	Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by Î² -adrenergic signaling. British Journal of Pharmacology, 2003, 140, 1019-1026.	2.7	18
162	Carvedilol. Drugs, 2003, 63, 1697-1741.	4.9	51
163	Cardiovascular Drug Therapy in the Elderly: Theoretical and Practical Considerations. Drugs and Aging, 2003, 20, 445-463.	1.3	23
164	Specialist Nurse Management Programmes. Pharmacoeconomics, 2003, 21, 225-240.	1.7	27
165	The effects of Â and Â blockade on ventilatory responses to exercise in chronic heart failure. British Heart Journal, 2003, 89, 1169-1173.	2.2	25
166	A RATIONAL BASIS FOR SELECTION AMONG DRUGS OF THE SAME CLASS. British Heart Journal, 2003, 89, 687-694.	2.2	9

#	Article	IF	Citations
167	Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. British Heart Journal, 2003, 89, 299-305.	2.2	76
168	Obstacles to the initiation of beta blockers for heart failure in a specialised clinic within a district general hospital. British Heart Journal, 2003, 89, 442-444.	2.2	5
169	Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. British Heart Journal, 2003, 89, 615-620.	2.2	140
170	Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. British Heart Journal, 2003, 89, 854-858.	2.2	55
171	Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. British Heart Journal, 2003, 89, 621-624.	2.2	25
172	Drug therapy in chronic heart failure. Postgraduate Medical Journal, 2003, 79, 634-642.	0.9	13
173	Long QTc predicts future cardiac death in stroke survivors. British Heart Journal, 2003, 89, 377-381.	2.2	42
174	Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart, 2004, 90, 866-870.	1.2	56
175	Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart, 2004, 90, 1248-1255.	1.2	98
176	Exercise capacity and cardiac function assessed by tissue Doppler imaging in chronic heart failure. Heart, 2004, 90, 1144-1150.	1.2	54
177	Comparison between tagged MRI and standard cine MRI for evaluation of left ventricular ejection fraction. European Radiology, 2004, 14, 1348-52.	2.3	17
178	Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic Dysfunction. Heart Failure Reviews, 2004, 9, 107-113.	1.7	10
179	The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure. Heart Failure Reviews, 2004, 9, 115-121.	1.7	14
180	Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?. Heart Failure Reviews, 2004, 9, 123-130.	1.7	46
181	Pharmacokinetics and Pharmacodynamics of Beta Blockers in Heart Failure. Heart Failure Reviews, 2004, 9, 131-137.	1.7	29
182	Beta Blockers as Anti-Arrhythmic Agents. Heart Failure Reviews, 2004, 9, 139-147.	1.7	10
183	Sex-Related Differences in Heart Failure and Beta-Blockers. Heart Failure Reviews, 2004, 9, 149-159.	1.7	13
184	Cardioprotective effects of carvedilol on acute autoimmune myocarditis. Molecular and Cellular Biochemistry, 2004, 259, 223-228.	1.4	10

#	Article	IF	Citations
185	Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle-branch block: Analysis of the multicenter insync randomized clinical evaluation (MIRACLE). Clinical Cardiology, 2004, 27, 678-682.	0.7	61
187	Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of ?-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1356-61.	3.3	35
188	Structure and function of coagulogen, a clottable protein in horseshoe crabs. Cellular and Molecular Life Sciences, 2004, 61, 1257-1265.	2.4	54
189	Is too much neurohormonal blockade harmful?. Current Cardiology Reports, 2004, 6, 169-175.	1.3	4
190	Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports, 2004, 1, 161-167.	1.3	1
191	Anemia and heart failure. Current Heart Failure Reports, 2004, 1, 176-182.	1.3	30
192	The changing epidemiology of sudden death in heart failure. Current Heart Failure Reports, 2004, 1, 93-97.	1.3	9
193	Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports, 2004, 1, 45-50.	1.3	69
194	Beta-blockers in heart failure: Is more better?. Current Heart Failure Reports, 2004, 1, 77-81.	1.3	0
195	Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. Current Heart Failure Reports, 2004, 1, 82-88.	1.3	1
196	Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with Î²-blocker therapy. Journal of Nuclear Cardiology, 2004, 11, 134-141.	1.4	28
197	Should we be screening for myocardial hibernation in heart failure?. Journal of Nuclear Cardiology, 2004, 11, 114-117.	1.4	3
198	Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure. Clinical Drug Investigation, 2004, 24, 9-15.	1.1	1
199	Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology, 2005, 28, 165-173.	0.7	28
200	Rationale for the use of angiotensin ii receptor blockers in patients with left ventricular dysfunction (part I of II). Clinical Cardiology, 2005, 28, 215-218.	0.7	0
201	Deciphering the sinus tachycardias. Clinical Cardiology, 2005, 28, 267-276.	0.7	23
202	The selectivity of Î² -adrenoceptor antagonists at the human Î² 1, Î² 2 and Î² 3 adrenoceptors. British Journal of Pharmacology, 2005, 144, 317-322.	2.7	436
203	Simulated Microgravity Induces Microvolt T Wave Alternans. Annals of Noninvasive Electrocardiology, 2005, 10, 363-370.	0.5	16

#	Article	IF	Citations
204	Treatment with angiotensin converting enzyme inhibitors, angiotensin-II-antagonists and beta-blockers in an unselected group of patients with chronic heart failure. European Journal of Clinical Pharmacology, 2005, 61, 209-214.	0.8	5
205	Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology, 2005, 206, 117-128.	1.0	34
206	Digitalis in heart failure! Still applicable?. Clinical Research in Cardiology, 2005, 94, 307-311.	1.2	46
207	Euro heart failure survey. Clinical Research in Cardiology, 2005, 94, 510-515.	1.2	21
209	Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure. Current Cardiology Reports, 2005, 7, 204-210.	1.3	12
210	Approach to antiarrhythmic therapy in patients with ICDs and frequent activations. Current Cardiology Reports, 2005, 7, 376-381.	1.3	8
211	When to initiate beta-blockers in heart failure: Is it ever too early?. Current Heart Failure Reports, 2005, 2, 94-99.	1.3	5
212	Management of hypertension in overweight and obese patients: A practical guide for clinicians. Current Hypertension Reports, 2005, 7, 330-336.	1.5	23
213	Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. Heart Failure Reviews, 2005, 10, 63-69.	1.7	8
214	Heart Failure Following Anterior Myocardial Infarction: An Indication for Ventricular Restoration, a Surgical Method to Reverse Post-Infarction Remodeling. Heart Failure Reviews, 2005, 9, 241-254.	1.7	9
215	Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?. Heart Failure Reviews, 2005, 9, 337-345.	1.7	11
216	Effect of a community heart failure clinic on uptake of Â blockers by patients with obstructive airways disease and heart failure. Heart, 2005, 92, 331-336.	1.2	29
217	Clinical assessment of myocardial hibernation. Heart, 2005, 91, 111-117.	1.2	27
218	Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart, 2005, 91, 489-494.	1.2	69
219	How strong is the evidence for the use of perioperative Î² blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2005, 331, 313-321.	2.4	366
220	Optimising the Use of ??-Adrenoceptor Antagonists in Coronary Artery Disease. Drugs, 2005, 65, 787-797.	4.9	58
221	??-Adrenoceptor Antagonists in Elderly Patients with Chronic Heart Failure. Drugs and Aging, 2006, 23, 93-99.	1.3	21
222	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology, 2006, 22, 23-45.	0.8	378

#	Article	IF	Citations
223	Cardioprotective medication use in hemodialysis patients. Canadian Journal of Cardiology, 2006, 22, 755-760.	0.8	39
224	Nebivolol. Drugs, 2006, 66, 1389-1409.	4.9	63
225	Cardiomyopathy, familial dilated. Orphanet Journal of Rare Diseases, 2006, 1, 27.	1.2	137
226	Effects of Angiotensin-Converting Enzyme Inhibitors in Systolic Heart Failure Patients With Chronic Kidney Disease: A Propensity Score Analysis. Journal of Cardiac Failure, 2006, 12, 499-506.	0.7	28
227	Outcomes in ambulatory chronic systolic and diastolic heart failure: A propensity score analysis. American Heart Journal, 2006, 152, 956-966.	1.2	63
228	Changes in heart failure medications in patients hospitalised and discharged. BMC Family Practice, 2006, 7, 69.	2.9	7
229	CHARITY: Cha gas car diomyopathy bi soprolol int ervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. Trials, 2006, 7, 21.	0.7	20
230	Brief report: Î²-blocker use among veterans with systolic heart failure. Journal of General Internal Medicine, 2006, 21, 1306-1309.	1.3	19
231	Metabolic and immunologic derangements in cardiac cachexia: where to from here?. Heart Failure Reviews, 2006, 11, 57-64.	1.7	25
232	Pharmacological treatment of chronic heart failure. Heart Failure Reviews, 2006, 11, 109-123.	1.7	29
233	The treatment of heart failure with preserved ejection fraction (â€œdiastolic heart failureâ€). Heart Failure Reviews, 2006, 11, 141-146.	1.7	30
235	Management of the cardiorenal syndrome in heart failure. Current Cardiology Reports, 2006, 8, 211-216.	1.3	14
236	The problem of polypharmacy in heart failure. Current Cardiology Reports, 2006, 8, 217-225.	1.3	28
237	Amiodarone: A multifaceted antiarrhythmic drug. Current Cardiology Reports, 2006, 8, 349-355.	1.3	42
238	Hurricanes and heart failure: A review of the who, what, when, and where of beta-blocker therapy. Current Heart Failure Reports, 2006, 3, 89-95.	1.3	5
239	Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports, 2006, 8, 185-190.	1.5	5
240	The latest generation of beta-blockers: New pharmacologic properties. Current Hypertension Reports, 2006, 8, 279-286.	1.5	18
241	Morphological aspects of apoptosis in heart diseases. Journal of Cellular and Molecular Medicine, 2006, 10, 56-75.	1.6	91

#	Article	IF	Citations
242	Effects of an interactive CD-program on 6 months readmission rate in patients with heart failure â€“ a randomised, controlled trial [NCT00311194]. BMC Cardiovascular Disorders, 2006, 6, 30.	0.7	27
243	Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. European Heart Journal, 2006, 27, 1431-1439.	1.0	398
244	Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure. Circulation, 2006, 114, 397-403.	1.6	539
245	A propensity-matched study of the effect of diabetes on the natural history of heart failure: variations by sex and age. Heart, 2006, 93, 1584-1590.	1.2	50
246	Long term prognosis of heart failure after acute coronary syndromes without ST elevation. Postgraduate Medical Journal, 2006, 82, 55-59.	0.9	10
247	Understanding chronic heart failure. Archives of Disease in Childhood, 2007, 92, 812-816.	1.0	8
248	The underuse of digoxin in heart failure, and approaches to appropriate use. Cmaj, 2007, 176, 641-643.	0.9	18
249	Necessary cautions when considering digoxin in heart failure. Cmaj, 2007, 176, 644-645.	0.9	4
250	Digoxin and Reduction in Mortality and Hospitalization in Geriatric Heart Failure: Importance of Low Doses and Low Serum Concentrations. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 323-329.	1.7	49
251	A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. European Heart Journal, 2007, 28, 1334-1343.	1.0	166
252	Î² blockers in hypertension and cardiovascular disease. BMJ: British Medical Journal, 2007, 334, 946-949.	2.4	51
253	Management of end stage cardiac failure. Postgraduate Medical Journal, 2007, 83, 395-401.	0.9	35
254	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Canadian Journal of Cardiology, 2007, 23, 21-45.	0.8	131
255	Î²-Adrenoceptor Antagonists in Elderly Patients with Heart Failure. Drugs and Aging, 2007, 24, 1031-1044.	1.3	14
256	Age- and Gender-Specific Incidence of Hospitalisation for Digoxin Intoxication. Drug Safety, 2007, 30, 431-436.	1.4	44
257	Metabolic Profile of Nebivolol, a ??-Adrenoceptor Antagonist with Unique Characteristics. Drugs, 2007, 67, 1097-1107.	4.9	93
258	Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Studyâ€â€The Digitalis Investigation Group study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the Digitalis Investigation Group Investigators. This manuscript was prepared using a limited access data set obtained by the National Heart, Lung, and Blood Institute and does not necessarily reflect the opinions or views of the Digitalis Investigation Gro. American Journal of Cardiology, 2007, 99, 393-398.	0.7	217
259	A Propensity Matched Study of New York Heart Association Class and Natural History End Points in Heart Failure. American Journal of Cardiology, 2007, 99, 549-553.	0.7	74

#	Article	IF	Citations
260	Effects of Discontinuation of Digoxin Versus Continuation at Low Serum Digoxin Concentrations in Chronic Heart Failure. American Journal of Cardiology, 2007, 100, 280-284.	0.7	33
261	Does NT-proBNP Remain a Sensitive Biomarker for Chronic Heart Failure after Administration of a Beta-blocker?. Clinical Cardiology, 2007, 30, 469-474.	0.7	5
262	Digoxin and mortality in atrial fibrillation: a prospective cohort study. European Journal of Clinical Pharmacology, 2007, 63, 959-971.	0.8	102
265	Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews, 2007, 12, 37-47.	1.7	25
266	Socio-economic analysis of cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 225-236.	0.6	3
267	Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure. Current Heart Failure Reports, 2007, 4, 99-102.	1.3	4
268	Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure. Current Heart Failure Reports, 2007, 4, 110-116.	1.3	0
269	Update on inotropic therapy in the management of acute heart failure. Current Treatment Options in Cardiovascular Medicine, 2007, 9, 443-449.	0.4	27
270	Medication adherence in heart failure. Heart Failure Reviews, 2008, 13, 99-106.	1.7	40
271	A propensity-matched study of the association of physical function and outcomes in geriatric heart failure. Archives of Gerontology and Geriatrics, 2008, 46, 161-172.	1.4	10
272	The prince and the pauper. A tale of anticancer targeted agents. Molecular Cancer, 2008, 7, 82.	7.9	73
273	Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. International Journal of Cardiology, 2008, 123, 138-146.	0.8	107
274	A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. International Journal of Cardiology, 2008, 125, 246-253.	0.8	69
275	The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study. Pulmonary Pharmacology and Therapeutics, 2008, 21, 134-141.	1.1	121
276	Ethnic Differences in Cardiovascular Drug Response. Circulation, 2008, 118, 1383-1393.	1.6	175
277	Beta-Arrestin-Mediated Signaling in the Heart. Circulation Journal, 2008, 72, 1725-1729.	0.7	46
278	Chronic heart failure: Î²-blockers and pharmacogenetics. European Journal of Clinical Pharmacology, 2009, 65, 3-17.	0.8	34
279	Effectiveness of Guideline-Recommended Cardiac Drugs for Reducing Mortality in the Elderly Medicare Heart Failure Population. Drugs and Aging, 2010, 27, 845-854.	1.3	8

#	Article	IF	Citations
280	Positive inotropes in heart failure: a review article. Heart Asia, 2012, 4, 16-22.	1.1	8
281	Î²-Adrenergic receptor antagonism in mice: a model for pediatric heart disease. Journal of Applied Physiology, 2013, 115, 979-987.	1.2	17
282	Device Therapies: New Indications and Future Directions. Current Cardiology Reviews, 2014, 11, 33-41.	0.6	9
283	Complex cardiac pacing in the setting of a district general hospital: procedural success and complications. Heart Asia, 2014, 6, 94-99.	1.1	1
284	Editorial: Reappraisal of increasing heart rate for cardiac performance. Journal of Cardiology Cases, 2014, 9, 170-171.	0.2	1
285	Evaluation of Synergistic Effects of Resynchronization Therapy and a Î²â€Blocker Upâ€titration Strategy Based on a Predefined Patientâ€Management Program: The <scp>RESTORE</scp> Study. Clinical Cardiology, 2015, 38, 2-7.	0.7	7
286	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clinical Science, 2015, 130, 57-77.	1.8	208
287	Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database. Scientific Reports, 2015, 5, 13692.	1.6	7
288	Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. BMC Cardiovascular Disorders, 2015, 15, 134.	0.7	32
289	Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase Î± in mouse. Cell and Bioscience, 2015, 5, 64.	2.1	31
290	Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation. Medicine (United States), 2015, 94, e2409.	0.4	19
291	Cardiac Magnetic Resonance Scar Imaging for Sudden Cardiac Death Risk Stratification in Patients with Non-Ischemic Cardiomyopathy. Korean Journal of Radiology, 2015, 16, 683.	1.5	22
292	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World Journal of Cardiology, 2015, 7, 808.	0.5	35
293	Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 515.	0.9	43
294	Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease. Therapeutics and Clinical Risk Management, 2015, 11, 189.	0.9	14
295	Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. Cardiology Research and Practice, 2015, 2015, 1-10.	0.5	17
296	Cardiac Innervation and Sudden Cardiac Death. Circulation Research, 2015, 116, 2005-2019.	2.0	300
297	Dronedarone-digoxin interaction in PALLAS: A foxglove connection?. Global Cardiology Science & Practice, 2015, 2015, 4.	0.3	1

#	Article	IF	Citations
298	Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators. Journal of Materials Science: Materials in Medicine, 2015, 26, 240.	1.7	2
299	The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229.	6.1	238
300	Cardiogenic shock induced by bisoprolol in a patient with CYP2D6 variant. A case report. Journal of Cardiology Cases, 2015, 11, 109-112.	0.2	0
301	Effects of Beta-Blocker Withdrawal in AcuteÂDecompensated Heart Failure. JACC: Heart Failure, 2015, 3, 647-653.	1.9	121
302	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary AtrialÂFibrillation Cohort. Journal of the American College of Cardiology, 2015, 65, 2691-2698.	1.2	76
303	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	0.7	138
304	Nemaline myopathy and heart failure: role of ivabradine; a case report. BMC Cardiovascular Disorders, 2015, 15, 5.	0.7	13
305	The impact of arterial load on left ventricular performance: an invasive haemodynamic study in severe mitral stenosis. Journal of Physiology, 2015, 593, 1901-1912.	1.3	8
306	Genotype-based clinical trials in cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 475-487.	6.1	37
307	Drug therapies in older adults (part 2). Clinical Medicine, 2015, 15, 155-159.	0.8	5
308	Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 66, 1431-1441.	1.2	116
309	Stageâ€dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. British Journal of Pharmacology, 2015, 172, 2369-2382.	2.7	14
310	Prognostic Significance of Imaging Myocardial Sympathetic Innervation. Current Cardiology Reports, 2015, 17, 62.	1.3	15
311	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, The, 2015, 351, h4451.	3.0	247
312	Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circulation: Heart Failure, 2015, 8, 733-740.	1.6	30
313	Autonomic control of the heart: going beyond the classical neurotransmitters. Experimental Physiology, 2015, 100, 354-358.	0.9	58
314	Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?. Cardiac Failure Review, 2016, 2, 47.	1.2	5
315	Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?. Cardiac Failure Review, 2016, 2, 35.	1.2	8

#	Article	IF	Citations
316	Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells. Stem Cells International, 2016, 2016, 1-15.	1.2	6
317	T-Tubular Electrical Defects Contribute to Blunted Î²-Adrenergic Response in Heart Failure. International Journal of Molecular Sciences, 2016, 17, 1471.	1.8	12
318	Heart Failure: Diagnosis, Management and Utilization. Journal of Clinical Medicine, 2016, 5, 62.	1.0	249
319	The Mechanism of Action of LCZ696. Cardiac Failure Review, 2016, 2, 40.	1.2	38
320	BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. Clinical Research in Cardiology, 2016, 105, 1021-1029.	1.5	18
321	Translational neurocardiology: preclinical models and cardioneural integrative aspects. Journal of Physiology, 2016, 594, 3877-3909.	1.3	133
322	Long-term use of secondary prevention medications for heart failure in Western Australia: a protocol for a population-based cohort study. BMJ Open, 2016, 6, e014397.	0.8	8
323	Relationship Between Î²â€Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 5, .	1.6	12
324	The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. Heart Failure Reviews, 2016, 21, 415-431.	1.7	6
325	Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies. Current Hypertension Reports, 2016, 18, 51.	1.5	7
326	Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 13.	0.4	6
327	Taxonomy of segmental myocardial systolic dysfunction. European Heart Journal, 2017, 38, ehw140.	1.0	11
328	Contemporary Controversies in Digoxin Use in Systolic Heart Failure. Current Heart Failure Reports, 2016, 13, 197-206.	1.3	9
329	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Current Diabetes Reports, 2016, 16, 116.	1.7	40
330	A meta-analysis of the effects of Î²-adrenergic blockers in chronic heart failure. Experimental and Therapeutic Medicine, 2016, 12, 2489-2496.	0.8	11
331	Is Heart Rate a Norepiphenomenon in Heart Failure?. Current Cardiology Reports, 2016, 18, 91.	1.3	0
332	Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. Trials, 2016, 17, 530.	0.7	6
333	Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2016, 7, 278-290.	1.1	35

#	Article	IF	Citations
334	Cumulative subgroup analysis to reduce waste in clinical research for individualised medicine. BMC Medicine, 2016, 14, 197.	2.3	11
335	Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?. Cardiology, 2016, 134, 311-319.	0.6	633
336	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. Clinical Medicine Insights: Cardiology, 2016, 10, CMC.S38444.	0.6	3
337	Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication. Drugs - Real World Outcomes, 2016, 3, 279-288.	0.7	5
338	Heart Failure Clinical Trials in East and Southeast Asia. JACC: Heart Failure, 2016, 4, 419-427.	1.9	48
339	Does modern medicine increase life-expectancy: Quest for the Moon Rabbit?. Indian Heart Journal, 2016, 68, 19-27.	0.2	32
340	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. Journal of Cardiac Failure, 2016, 22, 692-699.	0.7	13
341	Medical Therapy Leads to Favorable Remodeling in Left Ventricular Non-compaction Cardiomyopathy: Dilated Phenotype. Pediatric Cardiology, 2016, 37, 674-677.	0.6	17
342	Association of Digoxin With Interstage Mortality: Results From the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Use Dataset. Journal of the American Heart Association, 2016, 5, .	1.6	49
343	Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10â€Year Cohort. Journal of the American Heart Association, 2016, 5, .	1.6	26
344	New Targets in the Drug Treatment of Heart Failure. Drugs, 2016, 76, 187-201.	4.9	2
345	Heart failure â€“ what the general physician needs to know. Clinical Medicine, 2016, 16, 25-33.	0.8	1
346	Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine. American Journal of Cardiovascular Drugs, 2016, 16, 93-101.	1.0	1
347	â€œNihilismâ€•of chronic heart failure therapy in children and why effective therapy is withheld. European Journal of Pediatrics, 2016, 175, 445-455.	1.3	39
348	A perspective on sympathetic renal denervation in chronic congestive heart failure. Heart Failure Reviews, 2016, 21, 1-10.	1.7	6
349	Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management. Heart and Vessels, 2016, 31, 1109-1116.	0.5	10
350	Beta-blockers for hypertension. The Cochrane Library, 2017, 2017, CD002003.	1.5	205
351	Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. European Heart Journal, 2017, 38, ehw577.	1.0	40

#	Article	IF	Citations
352	Impact of Betaâ€Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Populationâ€Based Cohort Study. Journal of the American Heart Association, 2017, 6, .	1.6	13
353	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	1.6	178
354	Drug Therapy for Stable Angina Pectoris. Drugs, 2017, 77, 265-284.	4.9	32
355	Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clinical Research in Cardiology, 2017, 106, 501-513.	1.5	38
356	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clinical Research in Cardiology, 2017, 106, 711-721.	1.5	27
357	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. Cerebrovascular Diseases, 2017, 44, 43-50.	0.8	5
358	Novel selective Î² ₁ â€adrenoceptor antagonists for concomitant cardiovascular and respiratory disease. FASEB Journal, 2017, 31, 3150-3166.	0.2	16
359	Effect of Digoxin Use Among Medicaid Enrollees With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2017, 10, e004573.	2.1	6
360	Medications to Avoid in Acute Decompensated Heart Failure. Current Emergency and Hospital Medicine Reports, 2017, 5, 83-87.	0.6	0
361	Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure. Journal of the American Medical Directors Association, 2017, 18, 761-765.	1.2	5
362	Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. SAGE Open Medicine, 2017, 5, 205031211770005.	0.7	3
363	Left ventricular ejection fraction as therapeutic target: is it the ideal marker?. Heart Failure Reviews, 2017, 22, 641-655.	1.7	19
364	Current Pharmacological Therapies in Heart Failure Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 107-114.	1.0	21
365	The Real Role of Î²-Blockers in Daily Cardiovascular Therapy. American Journal of Cardiovascular Drugs, 2017, 17, 361-373.	1.0	79
366	Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar. International Journal of Clinical Pharmacy, 2017, 39, 1070-1083.	1.0	0
367	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Journal of Hypertension, 2017, 35, 2532-2536.	0.3	28
368	New horizons in cardiac innervation imaging: introduction of novel 18F-labeled PET tracers. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2302-2309.	3.3	21
369	Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 1543-1554.	1.2	65

#	Article	IF	Citations
370	Long-term management of end-stage heart failure. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 153-166.	1.7	22
371	Outcomes of patients with periprocedural atrial fibrillation undergoing percutaneous coronary intervention for chronic total occlusion. Clinical Research in Cardiology, 2017, 106, 986-994.	1.5	4
372	Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention. Clinical Drug Investigation, 2017, 37, 105-120.	1.1	3
373	Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Current Cardiology Reports, 2017, 19, 71.	1.3	147
374	Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East. BMJ Open, 2017, 7, e014915.	0.8	12
375	Invasive Treatment in Advanced (Stage-D) Heart Failure. , 0, , .		1
376	The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Archives of Medical Science, 2017, 5, 1207-1216.	0.4	26
377	Current Therapeutic Options for Heart Failure in Elderly Patients. BioMed Research International, 2017, 2017, 1-11.	0.9	13
378	Dasatinib and Prednisolone Induction Therapy for a Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Dilated Cardiomyopathy Accompanied by Life-Threatening Ventricular Tachycardia. Case Reports in Hematology, 2017, 2017, 1-4.	0.3	1
379	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	0.7	56
380	Should Digoxin Continue To Be Used for the Management of Atrial Fibrillation?. Canadian Journal of Hospital Pharmacy, 2017, 70, 391-394.	0.1	4
381	Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). Korean Circulation Journal, 2017, 47, 543.	0.7	24
382	Chronic heart failure. Australian Prescriber, 2017, 40, 128-136.	0.5	17
383	Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. Drug Design, Development and Therapy, 2017, Volume11, 305-312.	2.0	18
384	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fractionâ€"Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. American Heart Journal, 2018, 199, 97-104.	1.2	9
385	Î²-Blocker Dialyzability in Maintenance Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 604-611.	2.2	35
386	The heart failure burden of type 2 diabetes mellitusâ€"a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	1.7	41
387	Effect of Î²â€Blockers Beyond 3ÂYears After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	1.6	16

#	Article	IF	Citations
388	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. Clinical Medicine, 2018, 18, 138-145.	0.8	11
389	Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic. Journal of Drug Assessment, 2018, 7, 8-13.	1.1	2
390	Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently. Indian Heart Journal, 2018, 70, 201-203.	0.2	4
391	Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records. BMC Medical Informatics and Decision Making, 2018, 18, 24.	1.5	10
392	Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial. Trials, 2018, 19, 103.	0.7	4
393	How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care. Journal of Intensive Care, 2018, 6, 23.	1.3	9
394	The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Failure Reviews, 2018, 23, 527-535.	1.7	12
396	The Current Focus of Heart Failure Clinical Trials. Journal of Cardiac Failure, 2018, 24, 321-329.	0.7	4
397	Perioperative beta-blockers for preventing surgery-related mortality and morbidity. The Cochrane Library, 2018, 2018, CD004476.	1.5	45
398	Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines. Drugs, 2018, 78, 567-576.	4.9	7
399	Imaging of cardiac sympathetic activity in heart failure: Not out of the woods yet. Journal of Nuclear Cardiology, 2018, 25, 1172-1177.	1.4	3
401	Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Failure Reviews, 2018, 23, 27-36.	1.7	40
402	Lessons learned in acute heart failure. European Journal of Heart Failure, 2018, 20, 630-641.	2.9	33
403	Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart. Heart Failure Reviews, 2018, 23, 37-54.	1.7	38
404	Systematic review of economic burden of heart failure. Heart Failure Reviews, 2018, 23, 131-145.	1.7	103
405	A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan. PLoS ONE, 2018, 13, e0207481.	1.1	9
406	Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy. Journal of Arrhythmia, 2018, 34, 548-555.	0.5	3
407	Reasons for Guideline Nonadherence at Heart Failure Discharge. Journal of the American Heart Association, 2018, 7, e008789.	1.6	33

#	Article	IF	Citations
408	Effects of Bisoprolol Are Comparable with Carvedilol in Secondary Prevention of Acute Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention. Chonnam Medical Journal, 2018, 54, 121.	0.5	2
409	Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study. PLoS ONE, 2018, 13, e0205440.	1.1	0
410	ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to Î²-blockers in patients with heart failure. Cell Discovery, 2018, 4, 57.	3.1	26
411	Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling. Journal of Korean Medical Science, 2018, 33, e171.	1.1	2
412	Mihai Gheorghiade, MDâ€"Life and Concepts. American Journal of Therapeutics, 2018, 25, e453-e455.	0.5	0
413	Current drug therapy for heart failure with reduced ejection fraction. Herz, 2018, 43, 383-391.	0.4	7
414	Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. Clinical Research in Cardiology, 2018, 107, 1040-1049.	1.5	10
415	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2018, 6, CD012721.	1.5	56
416	Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors. Current Heart Failure Reports, 2018, 15, 270-279.	1.3	0
417	Reninâ€"angiotensinâ€"aldosterone inhibition improves right ventricular function: a meta-analysis. Heart Asia, 2018, 10, e010999.	1.1	7
418	SPECT vs. PET in cardiac innervation imaging: clash of the titans. Clinical and Translational Imaging, 2018, 6, 293-303.	1.1	19
419	The sodium pump and digitalis drugs: Dogmas and fallacies. Pharmacology Research and Perspectives, 2019, 7, e00505.	1.1	39
420	Does digoxin cause more harm than good?. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2019, 11, 165-170.	0.0	0
421	Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 405-411.	1.0	3
422	Carvedilol Among Patients With HeartÂFailure With a Cocaine-UseÂDisorder. JACC: Heart Failure, 2019, 7, 771-778.	1.9	9
425	Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients. Scientific Reports, 2019, 9, 453.	1.6	4
426	Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction. Circulation Research, 2019, 124, 1618-1632.	2.0	39
427	Stable Angina Medical Therapy Management Guidelines: A Critical Review of Guidelines from the European Society of Cardiology and National Institute for Health and Care Excellence. European Cardiology Review, 2019, 14, 18-22.	0.7	26

#	Article	IF	Citations
428	Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 30.	0.4	4
429	New drugs: big changes in conservative heart failure therapy?. European Journal of Cardio-thoracic Surgery, 2019, 55, i3-i10.	0.6	10
430	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	2.0	115
431	A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471984019.	1.0	12
432	Rationale and design of the DIGITâ€HF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq0 0 0 rgBT /Overlock 10 T Heart Failure, 2019, 21, 676-684.	2.9	51
433	Î²-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: A nationwide population-based observational study. PLoS ONE, 2019, 14, e0213187.	1.1	16
434	Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Heart Failure Reviews, 2019, 24, 499-510.	1.7	9
435	Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?. Korean Circulation Journal, 2019, 49, 249.	0.7	4
436	B-Type Natriuretic Peptides (BNP) and Tissue Doppler E/eÂ´ Before and After 4 Weeks Standard Treatment of African Heart Failure Subjects: The ABU-BNP Longitudinal Survey . Vascular Health and Risk Management, 2019, Volume 15, 559-569.	1.0	1
437	Questionable utility of digoxin in left-ventricular assist device recipients: A multicenter, retrospective analysis. PLoS ONE, 2019, 14, e0225628.	1.1	3
438	MitraClip: How Do We Reconcile the Inconsistent Findings of MITRA-FR and COAPT?. Current Cardiology Reports, 2019, 21, 150.	1.3	8
439	Association of Î²-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction. JAMA Network Open, 2019, 2, e1916598.	2.8	94
440	Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	0.8	2
441	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. American Journal of Therapeutics, 2019, 26, e222-e233.	0.5	10
442	Influence of OATP1B1 and OATP1B3 mutations and glomerular filtration rate on trough serum digoxin concentration in the Chinese population. Medicine (United States), 2019, 98, e15088.	0.4	0
443	Hemodynamic effects of inotropic drugs in heart failure. Medicine (United States), 2019, 98, e18144.	0.4	1
444	Impact of short-acting loop diuretic doses and cardiac sympathetic nerve abnormalities on outcomes of patients with reduced left ventricular function. Medicine (United States), 2019, 98, e14657.	0.4	5
445	Î²-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal, 2019, 40, 1399-1407.	1.0	66

#	Article	IF	Citations
446	Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. IJC Heart and Vasculature, 2019, 22, 1-5.	0.6	19
447	Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. Obstetric Medicine, 2019, 12, 66-75.	0.5	21
448	Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 343-351.	0.7	16
449	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	1.3	8
450	The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 782-789.	0.4	16
452	The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction. IJC Heart and Vasculature, 2020, 26, 100451.	0.6	10
453	Differences in medical treatment and clinical characteristics between men and women with heart failure â€“ a single-centre multivariable analysis. European Journal of Clinical Pharmacology, 2020, 76, 539-546.	0.8	11
454	Efficient removal of digoxin from aqueous solution using magnetic nanocomposite (Fe₃O₄â€“GOâ€“SO₃H) as an advanced nano-absorbent. Nanocomposites, 2020, 6, 66-75.	2.2	7
455	Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department. Egyptian Heart Journal, 2020, 72, 53.	0.4	5
456	The efficacy of baroreflex activation therapy for heart failure. Medicine (United States), 2020, 99, e22951.	0.4	4
457	Loop Diuretic Prescription and 30-DayÂOutcomes in Older Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 669-679.	1.2	41
458	Long-Term Effects of Angiotensin Receptorâ€“Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction. Diagnostics, 2020, 10, 522.	1.3	4
459	Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care. Netherlands Heart Journal, 2020, 28, 31-38.	0.3	5
460	Carvedilol Alters Circulating MiR-1 and MiR-214 in Heart Failure . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 375-383.	0.4	9
461	Effectiveness of Metoprolol in Improving Cardiac and Motor Functions in Patients with Chronic Heart Failure: A Prospective Study . Drug Design, Development and Therapy, 2020, Volume 14, 3485-3494.	2.0	0
462	Digoxin: Pharmacology and toxicologyâ€”A review. Environmental Toxicology and Pharmacology, 2020, 79, 103400.	2.0	56
463	Î²-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. Biomedicine Hub, 2020, 5, 1-10.	0.4	4
464	A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. British Journal of Clinical Pharmacology, 2020, 86, 1267-1280.	1.1	20

#	Article	IF	Citations
465	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	1.0	151
466	Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction. PLoS ONE, 2020, 15, e0233161.	1.1	0
467	Pharmacological interventions for heart failure in people with chronic kidney disease. The Cochrane Library, 2020, 2020, CD012466.	1.5	7
468	Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 139-147.	1.4	5
469	Impact of guideline-recommended versus non-guideline-recommended Î²-blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry. BMC Cardiovascular Disorders, 2020, 20, 8.	0.7	1
470	Adherence to betaâ€blockers and longâ€term risk of heart failure and mortality after a myocardial infarction. ESC Heart Failure, 2021, 8, 344-355.	1.4	10
471	Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence. ESC Heart Failure, 2021, 8, 3-15.	1.4	16
472	Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients. ESC Heart Failure, 2021, 8, 300-308.	1.4	5
473	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
474	Myocardial viability testing: all STICHed up, or about to be REVIVED?. European Heart Journal, 2022, 43, 118-126.	1.0	21
475	Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure. British Journal of Cardiology, 2021, , .	0.7	1
476	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680.	1.0	96
477	Realâ€world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMARTâ€•Registry. ESC Heart Failure, 2021, 8, 1675-1680.	1.4	7
478	Comparison of second appropriate defibrillator therapy occurrence in patients implanted for primary prevention and secondary prevention â€“ Sub-analysis of the Nippon Storm Study-. IJC Heart and Vasculature, 2021, 32, 100704.	0.6	2
479	Resting heart rate predicts all-cause mortality in sub-Saharan African patients with heart failure: a prospective analysis from the Douala Heart failure registry (Do-HF). Cardiovascular Diagnosis and Therapy, 2021, 11, 111-119.	0.7	4
480	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	1.4	20
481	Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacological Reviews, 2021, 73, 730-762.	7.1	80
482	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart, 2021, 8, e001585.	0.9	30

#	Article	IF	Citations
483	Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes. Human Molecular Genetics, 2021, 30, 1384-1397.	1.4	19
484	Development of an automated closed-loop Î²-blocker delivery system to stably reduce myocardial oxygen consumption without inducing circulatory collapse in a canine heart failure model: a proof of concept study. Journal of Clinical Monitoring and Computing, 2021, , 1.	0.7	1
485	Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Library, 2021, 2021, CD012721.	1.5	19
486	Recent advances in pharmacological treatment of heart failure. European Journal of Clinical Investigation, 2021, 51, e13624.	1.7	19
487	Therapeutic Properties of Highly Selective Î²-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2022, 36, 959-971.	1.3	8
488	Length of stay and readmission in older adults hospitalized for heart failure. Archives of Medical Science, 2021, 17, 891-899.	0.4	3
489	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	1.7	22
490	Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction. Journal of Taibah University Medical Sciences, 2021, 16, 582-590.	0.5	0
491	Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway. Bioscience Reports, 2021, 41, .	1.1	8
492	The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2847-2853.	0.5	12
493	Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients. Cardiology Research, 2021, 12, 2-9.	0.5	1
494	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 2416-2433.	1.8	27
495	Efficacy and safety of propranolol in infants with heart failure due to moderate-to-large ventricular septal defect (VSD-PHF study) â€“ A prospective randomized trial. Annals of Pediatric Cardiology, 2021, 14, 331.	0.2	5
496	Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease. Current Cardiology Reports, 2020, 22, 12.	1.3	6
497	Recent Advances: Cardiology II: Treatment of heart failure and atrial fibrillation and arrhythmias. BMJ: British Medical Journal, 1994, 309, 1631-1635.	2.4	8
498	Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations.. Journal of Clinical Investigation, 1990, 85, 1362-1371.	3.9	195
499	Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. Journal of Clinical Investigation, 2001, 107, 967-974.	3.9	173
500	Î²-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic GsÎ± mouse. Journal of Clinical Investigation, 1999, 104, 551-558.	3.9	113

#	Article	IF	Citations
501	Drug therapy for heart failure in older patients-what do they want?. Journal of Geriatric Cardiology, 2015, 12, 165-73.	0.2	16
502	Prediction of sudden death in elderly patients with heart failure. Journal of Geriatric Cardiology, 2018, 15, 185-192.	0.2	11
503	Cardiac Effects of Attenuating GsÎ± - Dependent Signaling. PLoS ONE, 2016, 11, e0146988.	1.1	2
504	Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure. PLoS ONE, 2017, 12, e0169743.	1.1	25
505	Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. Journal of Clinical Medicine Research, 2016, 8, 97-104.	0.6	3
506	Heart Failure in Women. Methodist DeBakey Cardiovascular Journal, 2021, 13, 216.	0.5	76
507	Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography. Echo Research and Practice, 2020, 7, G1-G18.	0.6	89
508	Gaps in the Heart Failure Guidelines. Cardiac Failure Review, 2015, 1, 50.	1.2	1
509	Expert Comment: Is Medication Titration in Heart Failure too Complex?. Cardiac Failure Review, 2017, 03, 25.	1.2	25
510	Gaps in the Heart Failure Guidelines. European Cardiology Review, 2014, 9, 104.	0.7	2
511	The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. Vascular Health and Risk Management, 2006, 2, 139-144.	1.0	3
512	Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure. Journal of Korean Medical Science, 2019, 34, e133.	1.1	11
513	Are patients in heart failure trials representative of primary care populations? A systematic review. BJGP Open, 2018, 2, bjgpopen18X101337.	0.9	6
514	Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure. International Journal of Heart Failure, 2020, 2, 73.	0.9	15
515	Sex and Gender Differences in Heart Failure. International Journal of Heart Failure, 2020, 2, 157.	0.9	43
516	Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?. International Journal of Heart Failure, 2020, 2, 145.	0.9	20
517	The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean Journal of Internal Medicine, 2019, 34, 1030-1039.	0.7	13
518	Management Of Atrial Fibrillation In Patients With Heart Failure. Journal of Atrial Fibrillation, 2014, 7, 1105.	0.5	1

#	Article	IF	Citations
519	Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. Journal of Atrial Fibrillation, 2013, 6, 751.	0.5	23
520	Update of treatment of heart failure with reduction of left ventricular ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2016, 1, 106-116.	0.5	8
521	Left ventricular remodelling in chronic primary mitral regurgitation: implications for medical therapy. Cardiovascular Journal of Africa, 2018, 29, 51-65.	0.2	19
522	The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy. Clinics, 2012, 67, 1063-1069.	0.6	14
523	2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. Acta Cardiologica Sinica, 2019, 35, 244-283.	0.1	50
524	Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review. Current Cardiology Reviews, 2022, 18, .	0.6	2
525	Transcriptional regulation by cAMP in the heart. , 2000, , 11-17.		7
526	Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers. Clinics, 2011, 66, 1275-1276.	0.6	0
527	Pharmacological Treatment of Patients with Chronic Systolic Heart Failure. European Cardiology Review, 2014, 9, 43.	0.7	1
528	Drugs to Avoid in Acute Decompensated Heart Failure (ADHF): Contraindicated Medications and Interactions. Contemporary Cardiology, 2017, , 261-268.	0.0	0
529	Digoxin for heart failure, obsolete or still useful?. Cardiologia Croatica, 2018, 13, 364-365.	0.0	0
530	Educational intervention to improve appropriate digoxin therapeutic drug monitoring: a quasi-experimental study. European Journal of Hospital Pharmacy, 2021, 28, 320-324.	0.5	1
531	Comparison of Nebivolol and Bisoprolol for Cardiovascular Mortality in Hypertensive Patients. Cureus, 2019, 11, e6453.	0.2	3
532	Pharmacist- or Nurse Practitionerâ€“Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	2
533	Preventing Cardiomyopathy in DMD. Neurology: Clinical Practice, 2021, 11, e661-e668.	0.8	8
534	The Impact of beta blockade on the cardio-respiratory system and symptoms during exercise. Current Research in Physiology, 2021, 4, 235-242.	0.8	10
535	Herbal glycosides in healthcare. , 2022, , 239-282.		9
536	Classification of Heart Failure: A Farewell to Ejection Fraction?. Anatolian Journal of Cardiology, 2020, 25, 2-6.	0.5	0

#	Article	IF	Citations
537	Cardiac Glycosides. , 2020, , 1-5.		0
538	Does left ventricular reverse remodeling influence long-term outcomes in patients with Chagas cardiomyopathy?. Cardiology Journal, 2022, 29, 44-52.	0.5	2
539	Pulmonary Hypertension, Sleep-Disordered Breathing, and Beta Blockers in Heart Failure Patients. Sleep and Breathing, 2002, 6, 181-187.	0.9	3
540	Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCEÂII, PROTECTÂI, and PROTECTÂIII Observational Studies. Advances in Therapy, 2022, 39, 391-404.	1.3	3
541	Association of Digoxin With Preserved Echocardiographic Indices in the Interstage Period: A Possible Mechanism to Explain Improved Survival?. Journal of the American Heart Association, 2021, 10, e021443.	1.6	5
542	Cardiac Glycosides. , 2021, , 410-414.		1
543	Cardiovascular therapeutics: A new potential for anxiety treatment?. Medicinal Research Reviews, 2022, 42, 1202-1245.	5.0	10
544	Myocardial strain to identify benefit from betaâ€blockers in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, , .	1.4	3
546	The Neutrophil-to-Albumin Ratio as a New Predictor of All-Cause Mortality in Patients with Heart Failure. Journal of Inflammation Research, 2022, Volume 15, 701-713.	1.6	11
547	Sacubitril/valsartan, sodiumâ€glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	1.2	5
548	Drug therapy for heart failure with reduced ejection fraction: what is the â€˜rightâ€™ dose?. European Journal of Heart Failure, 2022, 24, 421-430.	2.9	9
549	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. Korean Circulation Journal, 2022, 52, 173.	0.7	9
550	Digoxin Impact on Heart Failure Patients with Atrial Fibrillation. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2022, 76, 23.	0.4	3
551	Effect of Soil Type: Qualitative and Quantitative Analysis of Phytochemicals in Some Browse Species Leaves Found in Savannah Biome of South Africa. Molecules, 2022, 27, 1462.	1.7	5
552	The Beneficial Effects of Beta Blockers on the Long-Term Prognosis of Patients With Premature Atrial Complexes. Frontiers in Cardiovascular Medicine, 2022, 9, 806743.	1.1	2
553	Systems for the Functional Evaluation of Human Heart Tissues Derived from Pluripotent Stem Cells. Stem Cells, 2022, 40, 537-545.	1.4	3
554	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712.	1.6	57
555	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973.	0.5	8

#	Article	IF	Citations
556	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the <scp>S</scp>wedish Heart Failure Registry. European Journal of Heart Failure, 2022, 24, 871-884.	2.9	33
557	Therapeutic targets for cardiac fibrosis: from old school to next-gen. Journal of Clinical Investigation, 2022, 132, .	3.9	53
558	Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF). Cureus, 2022, 14, e22778.	0.2	4
559	Advanced heart failure: guidelineâ€directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Failure, 2022, 9, 1507-1523.	1.4	26
560	Chronic Digoxin Toxicity Leading to Institutionalization of an Elderly Woman. Canadian Journal of Hospital Pharmacy, 2022, 75, 118-121.	0.1	1
561	ï»¿Drug therapy monitoring (TDM) of Digoxin: safety and efficacy review. Pharmacia, 2022, 69, 261-264.	0.4	2
562	Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias. Pharmacology, 2022, 107, 35-45.	0.9	1
563	The Clinical Impact of Î²-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circulation Journal, 2022, 52, 544.	0.7	2
564	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	0.7	2
571	Relationships of Atrial Fibrillation at Diagnosis and Type of Atrial Fibrillation During Follow-up With Long-Term Outcomes for Heart Failure With Preserved Ejection Fraction. Circulation Reports, 2022, , .	0.4	1
572	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, .	1.2	1
573	Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. European Heart Journal Digital Health, 2022, 3, 284-295.	0.7	5
574	Periplocin Alleviates Cardiac Remodeling in DOCA-Saltâ€“Induced Heart Failure Rats. Journal of Cardiovascular Translational Research, 2023, 16, 127-140.	1.1	3
575	Analysis of Intoxication, Rehospitalization, and One-year Survival of Heart Failure Patients Receiving Digoxin at Harapan Kita National Cardiovascular Center, Jakarta, Indonesia: A Cross Section-observational Study. Current Drug Safety, 2023, 18, 246-252.	0.3	1
577	Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. Frontiers in Pharmacology, 0, 13, .	1.6	3
578	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.	1.0	15
579	Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 2022, 45, .	0.7	7
580	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. Clinical Research in Cardiology, 2023, 112, 111-122.	1.5	8

#	Article	IF	Citations
581	A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy. Scientific Reports, 2022, 12, .	1.6	3
582	Oral digoxin effects on exercise performance, K⁺ regulation and skeletal muscle Na⁺,K⁺â€ATPase in healthy humans. Journal of Physiology, 2022, 600, 3749-3774.	1.3	3
583	Reduction of heart failure guidelineâ€directed medication during hospitalization: prevalence, risk factors, and outcomes. ESC Heart Failure, 2022, 9, 3298-3307.	1.4	4
584	Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. Life, 2022, 12, 1112.	1.1	0
585	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
586	Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
587	Management of Heart Failure in Patients with Chronic Kidney Disease. European Cardiology Review, 0, 17, .	0.7	5
588	Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias. Journal of Cardiovascular Development and Disease, 2022, 9, 274.	0.8	0
589	Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. Journal of Clinical Medicine Research, 2022, 14, 315-320.	0.6	0
590	Management of heart failure with reduced ejection fraction. Heart, 0, , heartjnl-2020-318811.	1.2	4
591	Regulation of the microvasculature during small muscle mass exercise in chronic obstructive pulmonary disease vs. chronic heart failure. Frontiers in Physiology, 0, 13, .	1.3	2
592	Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure. ESC Heart Failure, 2023, 10, 66-79.	1.4	6
593	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. International Journal of Molecular Sciences, 2022, 23, 11336.	1.8	3
594	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. Current Heart Failure Reports, 2022, 19, 467-475.	1.3	2
595	Baroreflex activation therapy in advanced heart failure therapy: insights from a realâ€world scenario. ESC Heart Failure, 2023, 10, 284-294.	1.4	8
596	Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. Open Heart, 2022, 9, e001977.	0.9	4
597	Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. IJC Heart and Vasculature, 2022, 43, 101141.	0.6	0
598	Bibliometric and visual analysis of coronary microvascular dysfunction. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2

#	Article	IF	Citations
599	Pathophysiology and Management of Heart Failure in the Elderly. International Journal of Angiology, 0, , .	0.2	0
600	C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
601	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. Cardiovascular Research, 2023, 118, 3467-3481.	1.8	4
602	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. European Heart Journal Supplements, 2022, 24, L2-L9.	0.0	0
603	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. European Heart Journal Supplements, 2022, 24, L10-L19.	0.0	6
604	Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
605	Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Open Heart, 2022, 9, e002069.	0.9	0
606	Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. CJC Open, 2023, , .	0.7	0
607	Amiodarone vs. metoprolol succinate in HFrEF complicated with persistent atrial fibrillation with rapid ventricular response: A prospective observational study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
608	Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction. Autophagy, 2023, 19, 1803-1820.	4.3	5
609	Beta-blockers in cardiac arrhythmiasâ€“Clinical pharmacologistâ€™s point of view. Frontiers in Pharmacology, 0, 13, .	1.6	5
610	MiR-150 blunts cardiac dysfunction in mice with cardiomyocyte loss of Î²1-adrenergic receptor/Î²-arrestin signaling and controls a unique transcriptome. Cell Death Discovery, 2022, 8, .	2.0	1
611	Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0279680.	1.1	2
612	Acute Heart Failure: Diagnosticâ€“Therapeutic Pathways and Preventive Strategiesâ€”A Real-World Clinicianâ€™s Guide. Journal of Clinical Medicine, 2023, 12, 846.	1.0	4
613	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
614	Mapping the methodological diversity of published drug discontinuation studiesâ€”a scoping review of study topics, objectives, and designs. Trials, 2023, 24, .	0.7	0
615	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
616	Medication-Attributable Adverse EventsÂin HeartÂFailure Trials. JACC: Heart Failure, 2023, 11, 425-436.	1.9	1

#	Article	IF	Citations
617	The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients. ESC Heart Failure, 2023, 10, 1698-1705.	1.4	4
618	Endothelial, Vascular and Sympathetic Alterations as Therapeutic Targets in Chronic Heart Failure. Biomedicines, 2023, 11, 803.	1.4	1
619	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	0.8	0
620	Heart failure with reduced ejection fraction and atrial fibrillation: a Subâ€Saharan African perspective. ESC Heart Failure, 2023, 10, 1580-1596.	1.4	3
621	Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository. Drugs - Real World Outcomes, 0, , .	0.7	1
622	Arterial stiffness and its associations with left ventricular diastolic function according to heart failure types. Clinical Hypertension, 2023, 29, .	0.7	0
623	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics, 2023, 15, 1092.	2.0	1
624	Betaâ€blocker use and mortality among patients with systolic heart failure and pacemaker rhythm. ESC Heart Failure, 0, , .	1.4	1
625	Taurine and the Cardiovascular System: Focus on Mitochondrial-related Pathologies. , 2023, , 76-107.		0
626	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. Korean Circulation Journal, 2023, 53, 217.	0.7	4
627	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. International Journal of Heart Failure, 2023, 5, 66.	0.9	9
628	Optimal Heart Rate May Improve Systolic and Diastolic Function in Patients with Fontan Circulation. Journal of Clinical Medicine, 2023, 12, 3033.	1.0	0
629	Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial. Clinical Research in Cardiology, 2023, 112, 1096-1107.	1.5	2
631	Diagnosis and Management of Heart FailureÂin Children. , 2023, , 1-39.		0
633	Ventricular Septal Defects. , 2023, , 1-29.		0